Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Ms. Kimberly M. Jablonski

Chief Compliance & Ethics Officer

Dr. Joseph J. Eiden Jr.

Head of Medical Affairs

Ms. Sandra  Leung Esq.

Executive Vice President & General Counsel

Mr. Adam  Lenkowsky

Executive Vice President, Chief Commercialization Officer & Head of U.S. Oncology

Dr. Christopher S. Boerner Ph.D.

Chief Executive Officer & Chairman

Mr. David V. Elkins

Executive Vice President & Chief Financial Officer

Mr. Samit  Hirawat M.D.

Executive Vice President, Chief Medical Officer & Head of Development

Ms. Ahn Amanda Poole

Executive Vice President & Chief Human Resources Officer

Mr. Greg  Meyers

Executive Vice President and Chief Digital & Technology Officer

Mr. Timothy  Power

Vice President & Head of Investor Relations

Име	Пазарна капитализация
Marksans Pharma Limited	0M
Luye Pharma Group Ltd.	0M
Virbac SA	0M
Daiichi Sankyo Company, Limited	0M
Astellas Pharma Inc.	0M
NGL Fine-Chem Limited	0M
Eli Lilly and Company	0M
Tonghua Dongbao Pharmaceutical Co., Ltd.	0M
Orion Oyj	0M
Chugai Pharmaceutical Co., Ltd.	0M

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company Списък на конкурентите

Основни конкуренти